Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2 V617F Mutated Disease

Ayalew Tefferi, MD, Sravanthi Lavu, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4191.

https://doi.org/10.1182/blood.V130.Suppl_1.4191.4191

Published: 2017

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

Chiara Rossi, PharmD, Roberta Zini, BSc, PhD, Samantha Ruberti, BSc, PhD, Sebastiano Rontauroli, BSc, Zelia Prudente, BSc, PhD, Greta Barbieri, BSc, Elisa Bianchi, BSc, PhD, Simona Salati, BSc, PhD, Elena Genovese, BSc, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Enrico Tagliafico, MDPhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, Rossella Manfredini, BSc, PhD

Blood (2017) 130 (Supplement 1): 1655.

https://doi.org/10.1182/blood.V130.Suppl_1.1655.1655

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis

Samantha Ruberti, BSc, Elisa Bianchi, PhD, Tiziana Fanelli, MSc, Sebastiano Rontauroli, BSc, Valentina Pennucci, PhD, Giuditta Corbizzi Fattori, BSc, Carmela Mannarelli, MSc, PhD, Ruggiero Norfo, PhD, Chiara Rossi, BSc, Roberta Zini, PhD, Simona Salati, PhD, Zelia Prudente, PhD, Enrico Tagliafico, MDPhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD, Rossella Manfredini, PhDBSc

Blood (2016) 128 (22): 3132.

https://doi.org/10.1182/blood.V128.22.3132.3132

Published: 2016

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Tiziana Fanelli, MSc, Carmela Mannarelli, MSc, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4091.

https://doi.org/10.1182/blood.V126.23.4091.4091

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Blood (2015) 126 (23): 2830.

https://doi.org/10.1182/blood.V126.23.2830.2830

Published: 2015

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Blood (2014) 124 (21): 3192.

https://doi.org/10.1182/blood.V124.21.3192.3192

Published: 2014

Journal Articles

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Blood (2014) 124 (21): 3179.

https://doi.org/10.1182/blood.V124.21.3179.3179

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Blood (2014) 124 (21): 1867.

https://doi.org/10.1182/blood.V124.21.1867.1867

Published: 2014

NARROW

JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2 V617F Mutated Disease

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only